The potential of exosomes in immunotherapy of cancer

被引：51

作者：

Chaput, N

Taïeb, J

Schartz, N

Flament, C

Novault, S

André, F

Zitvogel, L

机构：

[1] Inst Gustave Roussy, INSERM, ERIT M, Unite Immunol,Dept Biol Clin, F-94805 Villejuif, France

[2] Hop La Pitie Salpetriere, Dept Gastroenterol & Hepatol, Paris, France

来源：

BLOOD CELLS MOLECULES AND DISEASES | 2005年 / 35卷 / 02期

关键词：

exosomes; cross presentation; MHC complexes; tumor; immunotherapy;

D O I：

10.1016/j.bcmd.2005.05.009

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Dendritic-cell-derived exosomes (DEX) secreted after dendritic cell loading with tumor peptides were found to mediate tumor rejection in mice. This observation prompted us to demonstrate that MHC class I/peptide complexes harbored onto exosomal membranes were capable of priming cytotoxic T cells and to mediate rejection of tumors expressing the relevant antigens. Moreover, DEX also promote NK cell activation in immunocompetent mice and NK cell-dependent antitumor effects. The first Phase I trial using DEX to immunize melanoma patients revealed the feasibility of DEX production in stage IV melanoma, their safety in long-term follow up and their bioactivity in vivo. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：111 / 115

页数：5

共 18 条

[1]

Exosomes as potent cell-free peptide-based vaccine.: I.: Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells [J].

André, F ;

Chaput, N ;

Schartz, NEC ;

Flament, C ;

Aubert, N ;

Bernard, J ;

Lemonnier, F ;

Raposo, G ;

Escudier, B ;

Hsu, DH ;

Tursz, T ;

Amigorena, S ;

Angevin, E ;

Zitvogel, L .

JOURNAL OF IMMUNOLOGY, 2004, 172 (04) :2126-2136

[2]

Malignant effusions and immunogenic tumour-derived exosomes [J].

Andre, F ;

Schartz, NEC ;

Movassagh, M ;

Flament, C ;

Pautier, P ;

Morice, P ;

Pomel, C ;

Lhomme, C ;

Escudier, B ;

Le Chevalier, T ;

Tursz, T ;

Amigorena, S ;

Raposo, G ;

Angevin, E ;

Zitvogel, L .

LANCET, 2002, 360 (9329) :295-305

[3]

Tumor-derived exosomes:: a new source of tumor rejection antigens [J].

André, F ;

Scharz, NEC ;

Chaput, N ;

Flament, C ;

Raposo, G ;

Amigorena, S ;

Angevin, E ;

Zitvogel, L .

VACCINE, 2002, 20 :A28-A31

[4]

Exosomes as potent cell-free peptide-based vaccine.: II.: Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection [J].

Chaput, N ;

Schartz, NEC ;

André, F ;

Taïeb, J ;

Novault, S ;

Bonnaventure, P ;

Aubert, N ;

Bernard, J ;

Lemonnier, F ;

Merad, M ;

Adema, G ;

Adams, M ;

Ferrantini, M ;

Carpentier, AF ;

Escudier, B ;

Tursz, T ;

Angevin, E ;

Zitvogel, L .

JOURNAL OF IMMUNOLOGY, 2004, 172 (04) :2137-2146

[5]

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].

Curiel, TJ ;

Coukos, G ;

Zou, LH ;

Alvarez, X ;

Cheng, P ;

Mottram, P ;

Evdemon-Hogan, M ;

Conejo-Garcia, JR ;

Zhang, L ;

Burow, M ;

Zhu, Y ;

Wei, S ;

Kryczek, I ;

Daniel, B ;

Gordon, A ;

Myers, L ;

Lackner, A ;

Disis, ML ;

Knutson, KL ;

Chen, LP ;

Zou, WP .

NATURE MEDICINE, 2004, 10 (09) :942-949

[6]

Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface [J].

Denzer, K ;

van Eijk, M ;

Kleijmeer, MJ ;

Jakobson, E ;

de Groot, C ;

Geuze, HJ .

JOURNAL OF IMMUNOLOGY, 2000, 165 (03) :1259-1265

[7]

Denzer K, 2000, J CELL SCI, V113, P3365

[8]

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes:: results of thefirst phase I clinical trial [J].

Escudier, B ;

Dorval, T ;

Chaput, N ;

André, F ;

Caby, MP ;

Novault, S ;

Flament, C ;

Leboulaire, C ;

Borg, C ;

Amigorena, S ;

Boccaccio, C ;

Bonnerot, C ;

Dhellin, O ;

Movassagh, M ;

Piperno, S ;

Robert, C ;

Serra, V ;

Valente, N ;

Le Pecq, JB ;

Spatz, A ;

Lantz, O ;

Tursz, T ;

Angevin, E ;

Zitvogel, L .

JOURNAL OF TRANSLATIONAL MEDICINE, 2005, 3 (1)

[9]

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative [J].

Ghiringhelli, F ;

Larmonier, N ;

Schmitt, E ;

Parcellier, A ;

Cathelin, D ;

Garrido, C ;

Chauffert, B ;

Solary, E ;

Bonnotte, B ;

Martin, F .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (02) :336-344

[10]

Exosomes as a tumor vaccine: Enhancing potency through direct loading of antigenic peptides [J].

Hsu, DH ;

Paz, P ;

Villaflor, G ;

Rivas, A ;

Mehta-Damani, A ;

Angevin, E ;

Zitvogel, L ;

Le Pecq, JB .

JOURNAL OF IMMUNOTHERAPY, 2003, 26 (05) :440-450

← 1 2 →